Navigation Links
Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29

Company to Proceed with Development Program for Oral Compounds to Treat Alcohol Dependence

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) today announced positive preliminary results from a clinical trial of ALKS 29 in alcohol dependent patients. Based on these results, the company plans to move forward with its development program for oral product candidates to treat alcohol dependence. ALKS 29 is a combination of two agents with distinct pharmacologic properties designed to provide advantages over current oral medications for the treatment of alcohol dependence. In the study, ALKS 29 was generally well tolerated and led to both a statistically significant increase in the percent of days abstinent and a decrease in drinking compared to placebo when combined with psychosocial therapy.

"We are encouraged by the positive results from this initial proof of concept study, which provide further rationale for the continued expansion of our addiction franchise," stated Elliot Ehrich, chief medical officer of Alkermes. "Addiction is an underserved disease area where a variety of treatments are needed that can improve outcomes for patients. We look forward to the complete analysis of these data, as we believe insights from this study could help pave the way for the development of ALKS 29 and other proprietary oral compounds for the treatment of alcohol dependence."

In the phase 1/2 study, patients treated with ALKS 29 demonstrated statistically significant improvement compared to placebo in terms of percent of days abstinent, percent of heavy drinking days, and average number of drinks per day. ALKS 29 was generally well tolerated during the study.

The phase 1/2 multi-center, randomized, double-blind, placebo-controlled, eight-week study was designed to assess the efficacy and safety of ALKS 29 in approximately 150 alcohol dependent patients. The study e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html ... soft tissues are the mass of cells that ... types of orthopedic soft tissues such as tendons, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html ... are structures in the human heart which control ... A person affected with heart valve diseases such ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... , PITTSBURGH, Dec. 22 Mylan Inc. (Nasdaq: MYL ... received tentative approval from the U.S. Food and Drug Administration ... for its New Drug Application (NDA) for Efavirenz Tablets, 50 ... in tablet form were developed by Matrix for use in ...
... , , , , , , CAPUA, Italy, Dec. 22 ... an agreement with Laboratoires Mayoly Spindler, Chatou Cedex, France, for ... process development and commenced cGMP manufacture of the Mayoly Spindler ... BioSolutions manufactures the lipase compound at its microbial fermentation facility ...
Cached Medicine Technology:Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4
(Date:8/27/2014)... The National League for Nursing is ... RN, FAAN, became the inaugural director of the ... the Science of Nursing Education , effective August 11. ... NLN Home for Transformative Excellence, established with the League’s ... , Under Dr. Dennis’s leadership, the NLN/Chamberlain Center ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Delta, a ... recently added several practical Cat D7R Dozers to its ... company’s senior spokesman has announced that all these items ... this promotion is to expand Delta’s market share in ... proud to launch the special offer; he has much ...
(Date:8/27/2014)... Lake Worth, FL (PRWEB) August 27, 2014 ... they are now a sponsor for Florida Mental Health ... to the benefits the new sponsorship is sure to ... meeting the professional needs of Florida’s licensed mental health ... division of the American Counseling Association (ACA) and since ...
(Date:8/27/2014)... August 27, 2014 The New York ... is holding free events about “ Sexuality & Intimacy ... Treston. These straightforward and entertaining discussions are for mature ... Mobility (501 Concord Avenue, Mamaroneck, NY) and October 7 ... Bethpage, NY). , The New York Mobility Club ...
(Date:8/27/2014)... The American College of ... management and treatment of pulmonary arterial hypertension (PAH) ... in Adults: CHEST Guideline, in the journal CHEST. ... and provide the latest and most accurate treatment ... Association (PHA) – the country’s leading pulmonary ...
Breaking Medicine News(10 mins):Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 2Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 3Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 4Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Millennium Treatment Group Sponsors Florida Mental Health Counselors Association 2Health News:Bussani Mobility Sponsors New York Mobility Club Meetings September 9 & October 7 for People with Disabilities, Sexuality & Intimacy Discussed by Advocate Liz Treston 2Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2
... Spain throughout the second half of the twentieth century. ... factors such as the advice of healthcare professionals, longer ... her level of education. "Up until not ... but things have changed in the second half of ...
... HealthDay Reporter , THURSDAY, Sept. 29 (HealthDay News) -- ... the globe, new research suggests that folks seem to awaken ... regardless of where they live. The novel study by ... people in 84 countries over two years, finding that work, ...
... IL Ben Franklin was right, at least on the healthy ... helped a cross-section of early-bird Australian youths keep slimmer and more ... the same amount of sleep. A study in the Oct. ... and wake times of 2,200 Australian participants, ages 9 to 16, ...
... , THURSDAY, Sept. 29 (HealthDay News) --,New genes associated ... large-scale analysis of genetic data related to the disease. ... six large databases for DNA data from about 10,000 ... In addition to validating results from previous research, ...
... has received a $750,000 grant from the Cleveland Foundation ... Stanley Hazen, M.D., Ph.D., will be ... spans a broad range of topics, from researching the ... identifying non-invasive testing for asthma. Recently, he published a ...
... in normal tissue may play a different role in colon ... researchers at the University of Illinois at Chicago College of ... skin and gut cells -- and in cancerous, but not ... the normal function of this protein in the gut, where ...
Cached Medicine News:Health News:Woman with a higher social standing and educational attainment breastfeed for longer 2Health News:Twitter Reflects World's Changing Moods 2Health News:Twitter Reflects World's Changing Moods 3Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Knockout of protein prevents colon tumor formation in mice 2
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma....
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... functions over a wide range of ... delivering more thorough characterization than other ... the relative change in the distribution ... way to measure heterogeneity, stoichiometry and ...
Medicine Products: